Form 8-K · Current report
News Corp 8-K, filed Sep 30, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000212
Summary
News Corp repurchased 62,323 Class A common shares for roughly US$1.77 million on September 29, 2026 under its 2025 repurchase program, which authorizes up to US$1 billion of Class A and Class B stock. Cumulative consideration paid under the program stands at about US$504.2 million.
Key points
- On September 29, 2026, News Corp bought back 62,323 Class A common shares for about US$1,771,549.97, at prices between US$28.18 and US$28.95.
- Cumulative repurchases under the 2025 Repurchase Program total 12,546,680 shares for approximately US$328,768,591.
- Total consideration paid under the program to date is approximately US$504,201,960 of the US$1 billion authorized.
- The program covers Nasdaq-listed Class A and Class B common stock and is executed in the open market or otherwise; no ASX-listed CDIs will be repurchased.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.